The drug will launch within a week, it said, with no news yet on pricing, although Biogen did tell Reuters it would be in line with other recently launched ALS treatments and out-of-pocket costs ...

If approved, tofersen would be the first treatment to target a genetic cause of ALS, albeit one ... by 25 January, and Biogen will also have to make the case for its drug at an advisory committee ...

Best Pharma Stocks to Invest in Now. In this article, we are going to take a look at where Biogen Inc. (NASDAQ:BIIB) stands ...

We recently published a list of 15 Small-Cap Healthcare Stocks Hedge Funds Are Buying. In this article, we are going to take ...

Just four months after Eli Lilly and British biotech Alchemab penned a discovery collaboration, the Big Pharma is licensing ...

May 1 (Reuters) - Biogen (BIIB.O), opens new tab beat first-quarter profit and revenue expectations on Thursday, as strong demand for its rare disease drugs helped offset declining sales of its ...

Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases. A Deep Dive into Biogen's Financials Market Capitalization ...

Sales of multiple sclerosis drugs such as Tecfidera fell 11% to $953 million. Sales of rare disease drugs, including Skyclarys and Spinraza, rose 33% to $563 million in the quarter. Revenue rose 6% to ...

Biogen's results beat estimates on strength ... January 6, 2025 Denali Therapeutics' ALS drug fails in mid-to-late stage trial Denali Therapeutics said on Monday its experimental drug failed ...

Biogen BIIB and partner Eisai announced that the European Commission (EC) has granted marketing authorization to Leqembi (lecanemab) for early Alzheimer’s disease (AD). The regulatory body has ...

Biogen Beats Q1 Earnings Expectations As Two Newcomer Drug Sales Spike, Avoids Tariff Impact Biogen beat Q1 earnings and revenue estimates, raised rare disease drug sales, and cut its 2025 EPS ...